The concept of using a stent to maintain patency of a lumen is not new. As early as 1969, stents were being investigated in the peripheral medal system as a means of preventing restenosis after dilatation by balloon angioplasty (Dotter, 1969 Fabian (Fabian, 1980) was the first to describe the use of a stent or spiral in the lower urinary tract. He placed a metallic endoprosthesis in the prosthetic urethra of poor surgical risk patients in urinary retention as a result of an enlarged prostate. Based upon these results and the successful outcome of others, it became clear that stenting of the lower urinary tract was a workable concept (Fabricius et al., 1983;Flier and Seppelt, 1987).At the present time, there are a number of intraurethral endoprostheses being developed for use in the lower urinary tract. However, the two permanently implanted intraurethral stents that have been investigated most extensively in both Europe and the United States are the Intraprostatic Stent by advance surgical intervention (San Clemente, California), and the UroLume Endoprosthesis,